Pargluva (generic name: muraglitazar) is sponsored by Bristol-Myers Squibb and Merck, and is a member of a new class of drugs known as dual PPAR-agonists. These are non-insulin drugs intended for type 2 diabetes patients in order to control their blood sugar and improve cholesterol levels by stimulating certain receptors in cells that are responsible for regulating fat and sugar. These drugs are designed at reducing blood sugar levels while increasing levels of so called "good" cholesterol. Type 2 diabetes affects approximately 18 million individuals, and is the most widespread form of diabetes.

Pargluva is only a proposed type 2 diabetes medicinal drug and is not yet FDA approved. An advisory committee for the FDA voted 8-1 recommending approval of the new diabetes drug. Recently, Pargluva received a setback in the approval process when an article appeared on the web page of the Journal of the American Medical Association that cited major heart attack and stroke risks from the new drug. Reports show that those taking Pargluva had approximately two times the risk of heart attack, stroke, or death compared to placebo patients. In Pargluva trials, 2.11% of patients who were treated with Pargluva suffered cardiovascular problems ranging from heart attack and stroke to congestive heart failure. In contrast, the control group had cardiovascular problems at the rate of only 0.81%.

Pargluva is still approvable, but the FDA has requested additional information concerning cardiovascular problems and the FDA has said that Pargluva would be approvable only after additional completed studies of the drug are reviewed.